From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Oxidized low density lipoprotein (Human) (Human ox-LDL) is involved in atherogenesis. Oxidized low density lipoprotein (Human) induces endothelial dysfunction via cytoplasmic adapter protein TRAF3IP2. Oxidized low density lipoprotein (Human) can stimulate the activation of endothelial cells and the production of adhesion molecules, and inhibits eNOS activity and NO production. Oxidized low density lipoprotein (Human) can activate NLRP3 inflammasome in macrophages .
Oxidized low density lipoprotein (mouse) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration .
ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC50 value of 1.5 µM. ASM-IN-1 reduces lipid plaques in the aortic arch and aorta and reduces plasma ceramide concentration and Ox-LDL levels. ASM-IN-1 shows antiatherosclerotic and anti-inflammatory activity .
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins(oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic. Many of these substances were isolated and purified from oxLDL and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position. PAz-PC (Azelaoyl PC) is one of the predominant oxLDL species and may be one of the important structural determinants of oxLDL.
Antioxidant agent-5 (compound D-6) is a potent antioxidant agent. Antioxidant agent-5 can inhibit oxLDL (oxidized low-density lipoprotein)-induced apoptosis and the expression of ICAM-1 and VCAM-1 in VECs. Antioxidant agent-5 suppresses oxLDL-induced increase of ROS level and nuclear translocation of NF-κB. Antioxidant agent-5 protects against oxLDL-induced endothelial injury by activating Nrf2/HO-1 anti-oxidation pathway .
Nrf2 activator-9 (compound D-36) is an Nrf2 activator that inhibits oxidized low-density lipoprotein (oxLDL) and high glucose (HG)-induced apoptosis in HUVEC cells. Nrf2 activator-9 inhibits oxLDL and HG-induced vascular endothelial cell (VEC) injury and can effectively prevent and treat atherosclerosis .
POVPC is an oxidized phospholipid can be found in in oxidatively modified low density lipoprotein (oxLDL). POVPC inhibits VSMC growth in high serum condition. POVPC induces apoptosis in low serum condition .
BI-0115 is a selective inhibitor of LOX-1 (IC50=5.4 µM) that blocks cellular uptake of oxLDL. BI-0115 binding triggers receptor inhibition by formation of dimers of the homodimeric ligand binding domain .
oxLig-1 (7-Ketocholesteryl-9-carboxynonanoate) is the lipid moiety of oxidized low-density lipoprotein (oxLDL) and is a key ligand for β-glycoprotein I (β(2)-GPI). oxLig-1 causes nuclear translocation by activating the NF-κB pathway. oxLig-1 can be used in the study of atherosclerosis (AS) .
Oxidized low density lipoprotein (Human) (Human ox-LDL) is involved in atherogenesis. Oxidized low density lipoprotein (Human) induces endothelial dysfunction via cytoplasmic adapter protein TRAF3IP2. Oxidized low density lipoprotein (Human) can stimulate the activation of endothelial cells and the production of adhesion molecules, and inhibits eNOS activity and NO production. Oxidized low density lipoprotein (Human) can activate NLRP3 inflammasome in macrophages .
Oxidized low density lipoprotein (mouse) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration .
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins(oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .
The LOX-1/OLR1 protein is a receptor on vascular endothelial cells that promotes the recognition, internalization, and degradation of oxidatively modified low-density lipoprotein (oxLDL). This process is indicative of atherosclerosis and triggers endothelial cell activation, pro-inflammatory responses, oxidative conditions, and apoptosis. LOX-1/OLR1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived LOX-1/OLR1 protein, expressed by HEK293 , with N-His labeled tag. The total length of LOX-1/OLR1 Protein, Mouse (HEK293, His) is 304 a.a., with molecular weight of 55-63 kDa.
The OLR1 protein is a receptor on vascular endothelial cells that plays a key role in the recognition, internalization, and degradation of oxidatively modified low-density lipoprotein (oxLDL). As a marker of atherosclerosis, oxLDL induces activation of vascular endothelial cells, leading to proinflammatory responses, oxidative conditions, and apoptosis. OLR1 Protein, Human (HEK293, His) is the recombinant human-derived OLR1 protein, expressed by HEK293 , with C-6*His labeled tag.
ox-LDL: LDL (Copper oxidized); Cu2SO4 oxidized low density lipoprotein; oxidized low density lipoprotein; Low density lipoprotein; MDA oxidized LDL; MDA oxidized low density lipoprotein. 氧化型低密度脂蛋白；
ELISA, IHC-P, IHC-F, FC, ICC/IF
Human
ox-LDL Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-ox-LDL polyclonal antibody. ox-LDL Antibody can be used for: ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, background without labeling.
LOX 1 Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-LOX 1 polyclonal antibody. LOX 1 Antibody can be used for: WB, IF-Cell, IHC-P, FC expriments in human, mouse background without labeling.
Product Comparison
Compare
Clear All
Compare Products
Products
In-stock
-
+
Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
YesNo
Size
* This product has been "discontinued".
Optimized version of product available:
/
In-stock
-
+
Add to Cart
Get quote
Inquiry Online
Your information is safe with us. * Required Fields.
